FK614 is a structurally novel class of peroxisome proliferator-activated receptor g g (PPARg g) agonist, with the mechanism of its insulin-sensitizing action most likely due to activation of PPARg g. In this study, properties of FK614 for PPARg g binding, ability to induce conformational change, and coactivator recruitment were investigated. FK614, rosiglitazone, and pioglitazone competed specific binding of 
Thiazolidinedione (TZD) compounds, such as rosiglitazone and pioglitazone, are anti-diabetic agents that improve insulin resistance. The action of TZDs is due to activation of peroxisome proliferator-activated receptor g (PPARg), a member of the nuclear hormone receptor (NHR) family of ligand-activated transcription factors. 1, 2) However, since weight gain and edema have been reported as side effects of these drugs, 3) improvement of PPARg agonists as anti-diabetic agents is still required. Furthermore, to offer a promising therapeutic approach to not only diabetes but also metabolic syndrome, new types of PPARg agonists, that can improve dyslipidemia, are likely to be beneficial.
Under physiological conditions, activity of PPARg is controlled by endogenous ligands. 9(S)-Hydroxyoctadecadienoic acid (HODE), which is one of the most potent endogenous ligands, 4) is an oxidation product of linoleic acid and a major oxidized lipid component of oxidized low density lipoprotein (LDL), 5) present at high levels in atherosclerotic lesions. 6) 9(S)-HODE is able to directly bind to PPARg with affinities in the micromolar range and activate transcription of PPARg target genes. 4) PPARg and 9(S)-HODE are reported to be involved in many cellular events, including fatty acid influx, foam cell formation, 4) vascular endothelial growth factor (VEGF) expression, 7) and cholesterol efflux in macrophages. 8, 9) Olefsky and Saltiel have suggested that PPARg activators might not function purely as agonists for the receptor, but also antagonize the effects of endogenous ligands. 10, 11) Several lines of studies have suggested that the binding of different PPARg ligands can induce a range of distinct PPARg conformations. [12] [13] [14] [15] Conformational differences in ligand-PPARg complexes lead to differential interactions with cofactors and exert differential regulation of activation on PPARg-responsible genes. 10, 16) Such cofactors interact with NHRs and they can either repress or enhance transcriptional activities. 17) In general, an unactivated NHR is complexed with a corepressor, such as nuclear receptor corepressor (NCoR), which extinguishes their transcriptional activity by histone deacetylase, when ligand is absent. 18) Upon binding with agonists, an NHR undergoes a conformational change that promotes the recruitment of coactivators, such as cyclic AMP response element-binding protein (CREB)-binding protein (CBP) 19) and steroid receptor coactivator 1, 20) that have histone acetyltransferase activity. Coactivator complexes facilitate target gene transcription by local chromatin remodeling 21) and bridging between an NHR and basal transcriptional machineries. 22) Recently, we reported that the novel non-TZD compound [3-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3-Hbenzimidazole-5-carboxamide] (FK614) substantially improves hyperglycemia, hypertriglyceridemia, hyperinsulinemia, and glucose intolerance in genetically obese and diabetic animal models. 23) FK614 has been shown to promote PPARg-mediated transcription in a cell-based reporter gene assay, 23) suggesting that FK614 exerts its pharmacological effects through PPARg activation. Despite FK614 producing a robust anti-diabetic effect in vivo, this compound appears to be a partial agonist of PPARg mediated transactivation in vitro. 23) Considering that FK614 behaves as a partial agonist of PPARg, 23) it is likely that antagonistic cross talk exists between FK614 and endogenous ligands. In this study, whether FK614 directly induces conformational changes in PPARg, produces specific alterations in PPARg conformation, and induces differential interaction with coactivators compared to ). FK614, rosiglitazone, and pioglitazone were synthesized at Astellas Pharma Inc. (Tokyo, Japan). 9(S)-HODE was purchased from Larodan Fine Chemicals (Malmö, Sweden). Streptavidin-conjugated allophycocyanin (SA-APC) and europium-conjugated anti-glutathione S-transferase (GST) antibody (Eu-anti-GST antibody) were from PerkinElmer Life and Analytical Sciences (Boston, MA, U.S.A.), respectively. All other chemicals and reagents were purchased from Sigma or Nacalai Tesque (Kyoto, Japan).
Plasmids Human PPARg1 and PPARg2 24) were cloned by reverse transcriptase-polymerase chain reaction (RT-PCR) with human adipose tissue and liver cDNA as templates, respectively. Full length cDNA for human PPARg1 was cloned into pCDM8 (Invitrogen, Carlsbad, CA, U.S.A.). The resultant plasmid, pCDM8-hPPARg1, was used for in vitro translation of human PPARg1. Expression plasmids for GST fusion protein were generated by insertion of full-length human PPARg2 or the ligand-binding domain (LBD) of human PPARg into pGEX-4T-3 or pGEX-4T-2 vector (Amersham Bioscience), respectively. Full length cDNA for human CBP 19) was amplified by RT-PCR with human lung cDNA as template and cloned into pcDNA3.1 (Invitrogen). The resultant plasmid, pcDNA3.1-hCBP, was used for in vitro translation of human CBP.
Ligand Binding Assay LBD of human PPARg was expressed as a GST fusion protein (GST-hPPARgLBD) in Escherichia coli strain BL21(DE3)pLysS. Pelleted cells were lysed and the soluble extract was clarified by centrifugation. Bacterial lysates containing GST-hPPARgLBD were stored at 4°C after measurement of protein concentration and dilution. Control extracts containing GST alone were also prepared for non-specific binding. Bacterial extract containing GST-hPPARgLBD or GST alone was incubated on ice for 3 h with 15 Limited Protease Sensitivity Assay pCDM8-hPPARg1 plasmids were used to synthesize [ 35 S]methionine-labeled full length human PPARg1 in a coupled transcription/translation system (Promega, Madison, WI, U.S.A.). Transcription/ translation reactions were equally aliquoted, then diluted test compounds were added. These mixtures were incubated for 30 min at room temperature, then distilled water or increasing concentrations of trypsin was added. Protease digestion was allowed to proceed for 20 min at 25°C, then was terminated by addition of SDS sample loading buffer and boiled for 1 min at 100°C. Resulting solutions were resolved by SDS-PAGE, then radio-labeled digestion products were visualized by autoradiography using a bio-imaging analyzer BAS2000 (Fuji Photo Film, Tokyo, Japan). Autoradiograms were analyzed using image analyzing software (ATTO Densito Graph 4.0, ATTO, Tokyo, Japan), and molecular mass of protected fragments was measured. Experiments were performed 3 times. Measurement of molecular mass was performed in all 3 experiments, then the mean was calculated for 3 experiments.
GST Pull-Down Assay Full-length human PPARg2 was expressed as a GST fusion protein (GST-hPPARg2) in Escherichia coli strain BL21. GST-hPPARg2 was purified using glutathione-Sepharose 4B beads. [ ]-labeled human CBP was incubated with GSThPPARg2 and glutathione-Sepharose 4B beads in the presence or absence of compounds in binding buffer (8 mM Tris-HCl, pH 7.6, 120 mM KCl, 8% glycerol, 0.5% 3-[(3-cholamidopropyl) dimethylammonio]-1-propane-sulfonate, 1 mg/ml BSA, 1 mM DTT, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mg/ml pepstatin). These mixtures were incubated overnight at 4°C, and beads were washed 4 times to remove unbound coactivators. Bound proteins were extracted into SDS sample loading buffer, then separated by SDS-PAGE. Bound CBP was visualized by autoradiography and quantitated by counting radioactivity using a BAS2000. Experiments were performed 3 or 4 times. EC 50 values for human CBP recruitment were determined by nonlinear curve fitting using Statistical Analysis System (SAS) (SAS Institute, Cary, NC, U.S.A.). Each EC 50 value was calculated under conditions where the maximum recruitment activity induced by each ligand was 100%. Significant difference of the values of CBP recruitment between non-treated control group and each ligand treated groups was assessed by Dunnett's multiple comparisons using SAS. Statistical significance was assumed at pϽ0.05.
Homogeneous Time-Resolved Fluorescence (HTRF) Assay Amino acid sequences of cofactor peptides, tagged at the N termini with biotin, used in HTRF assays were as follows: human CBP (N-Biotin-SGNLVPDAASKHKQLS-ELLRGGSGS-C), 19) human NCoR (N-Biotin-ADPASNL-GLEDIIRKALMGSF-C).
18) GST-hPPARg2 (50 nM) was incubated with 3 nM Eu-anti-GST antibody, 150 nM SA-APC, and 300 nM biotin-peptide in the absence or presence of compounds in 100 ml of assay buffer (10 mM HEPES, pH 7.6, 1 mM DTT, 100 mM NaCl, 0.05% Tween 20, 1 mg/ml BSA) for 16 h at 4°C. The assay was performed in a 96-well black plate (Nalge Nunc International, Rochester, NY, U.S.A.) and fluorescence was measured using an ARVO HTS multilabel counter (PerkinElmer Life and Analytical Sciences). HTRF signal was expressed as the ratio of emission intensities at 665 : 615 nm multiplied by a factor of 1000. For saturation experiments, GST-hPPARg2 (10 nM) was incubated with 5 nM Eu-anti-GST antibody, 600 nM SA-APC, in the presence of 10 mM FK614, 10 mM rosiglitazone, or 100 mM pioglitazone with various concentrations of non-labeled and biotin-labeled CBP peptides with a molar ratio of 50 : 1, in 100 ml of assay buffer for 16 h at 4°C. Nonspecific binding was determined in the presence of 2 mM unlabeled CBP peptide. Specific binding of CBP peptide to human PPARg2 is evaluated by subtracting the HTRF signal of nonspecific binding from the HTRF signal of total binding. Experiments were performed 3 times. EC 50 values were determined by nonlinear curve fitting using SAS. Each EC 50 value for coactivator recruitment was calculated under conditions where the maximum recruitment activity induced by each ligand is 100%. EC 50 value for NCoR dissociation was calculated under conditions where the amount of NCoR binding to PPARg in the absence of the ligand was 0% and HTRF signal in the absence of GSThPPARg2 was 100%. Estimated K d values for CBP peptide binding to ligand-PPARg complex were determined by linear regression analysis using GraphPad Prism. (Fig. 1) . This indicates that FK614 can bind directly to PPARg, similar to TZDs such as rosiglitazone and pioglitazone. It appears that FK614 is a high-affinity PPARg ligand with a K i value of 11 nM. Binding affinity of FK614 was 4.3-and 120-fold higher than that of rosiglitazone (K i : 47 nM) and pioglitazone (K i : 1.3 mM), respectively (Table 1) . FK614 shows a distinctly steeper slope of the displacement curve compared to rosiglitazone and pioglitazone (Fig. 1) . The Hill coefficient for FK614, rosiglitazone, and pioglitazone was 3.2, 1.3, and 1.2, respectively. The distinct property of FK614 for binding to PPARg is probably due to different conformational changes of the PPARg in response to binding of alternative ligands.
RESULTS

Ability of FK614 to Interact Directly with PPARg
Alteration in Conformations of PPARg g Induced by FK614 and Rosiglitazone To determine whether FK614 can directly induce conformational change in PPARg and whether FK614 produces specific alterations in PPARg conformation, the limited trypsin digestion of a full-length human PPARg1 was performed. Human PPARg1 labeled with [ 35 S]methionine was pre-incubated with dimethyl sulfoxide (DMSO) (vehicle), 10 mM FK614, or 10 mM rosiglitazone, then digested with various concentrations of trypsin (Fig. 2) . Incubation of the receptor with various concentrations of trypsin in the absence of ligand led to complete digestion of human PPARg1. In contrast, rosiglitazone produced protease resistant fragments, a major 22 kDa and a minor 32 kDa fragment, following partial protease digestion. The protease protection pattern was similar to previous results reported by Elbrecht et al. 24) FK614 also generated protease resistant fragments, however, a distinct digestion pattern was identified. FK614 induced stronger protection than rosiglitazone, and the 32 kDa fragment was detected more clearly than in the rosiglitazone-treated samples. In addition, a 25 kDa fragment found in FK614-bound receptor was faintly detected. Thus the results indicate that these two lig- 
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a) The amount of full length CBP recruitment was not obtained at the saturating concentration for pioglitazone in GST pull-down assay, therefore EC 50 value is estimated to be greater than 1200 nM for pioglitazone in that assay. ands interact with PPARg directly and induce distinct PPARg conformations.
Ligand Type-Specific Differential Interaction of PPARg g with Cofactors To determine whether FK614 directly promotes coactivator recruitment as an agonist and to address FK614-induced differential interaction with coactivators compared to other compounds, the effect of FK614, rosiglitazone, and pioglitazone on recruitment of CBP to PPARg by GST pull-down assay was studied. GST-hPPARg2 was incubated with [ 35 S]methionine-labeled human CBP in the absence or presence of various concentrations of ligands (Fig.  3) . FK614, rosiglitazone, pioglitazone, and 9(S)-HODE promoted the recruitment of CBP to PPARg in a concentration dependent manner. In response to rosiglitazone, an obvious increase in recruitment of CBP was obtained at 10 nM, reaching a plateau at 1 mM. Maximal recruitment of CBP in rosiglitazone-bound receptor was approximately 6-fold above basal level. Induction of CBP recruitment for pioglitazone and 9(S)-HODE was initiated at 10 nM and 1 mM, respectively, and maximal response was achieved at 100 mM or higher. Magnitude of CBP binding to PPARg at the highest concentration was similar in the 3 ligands. In contrast, FK614 exhibited a mechanistically different property in the concentration response curve for CBP recruitment. FK614 significantly promoted CBP recruitment to PPARg at 10 nM and higher concentrations. Maximal level of CBP recruitment induced by FK614 was about 2-fold above basal level. These results indicate that FK614 can induce recruitment of CBP to PPARg as a potent agonist for PPARg, and shows differential properties in coactivator recruitment compared to other ligands, presumably due to the distinct conformational change of PPARg induced by FK614.
Transcriptional activity of PPARg is regulated by dissociation or association with corepressors and coactivators in a ligand dependent manner. 10) To examine the effects of FK614 on coactivator or corepressor interaction, HTRF assays using peptides derived from the receptor interaction domain of corepressors or coactivators were performed. Figure 4A shows that HTRF signal was increased by recruitment of peptide from human CBP in the presence of various concentrations of FK614, rosiglitazone, and pioglitazone. However, the maximum response of FK614 was lower than that of the other 2 compounds. Results were similar to those observed in GST pull-down assays using full-length human CBP. In the absence of ligand, NCoR-PPARg interaction-dependent HTRF signal was observed, indicating that peptide from human NCoR was constitutively bound to PPARg (Fig. 4B) . FK614, rosiglitazone, and pioglitazone promoted dissociation of NCoR peptide from PPARg in a concentration dependent manner (Fig. 4B) . At 10 mM FK614, 10 mM rosiglitazone, and 100 mM pioglitazone, the level of PPARg binding to NCoR peptide was 2.8, 5.0, and 5.9% of control levels, respectively. These results indicate that FK614 promotes release of the constitutive interaction between corepressor and non-ligand bound PPARg as efficaciously as rosiglitazone and pioglitazone. Using this assay, EC 50 values of FK614, rosiglitazone, and pioglitazone for corepressor dissociation and coactivator recruitment were determined (Table 1) . EC 50 values of FK614 for CBP recruitment were 4.6-and 54-fold smaller than that of rosiglitazone and pioglitazone, respectively. FK614 was 6.1-and 120-fold more potent than rosiglitazone and pioglitazone, respectively, for NCoR dissociation. Interestingly, EC 50 values of each compound for NCoR dissociation were higher than that for CBP recruitment. These results suggest that affinity of PPARg ligands for corepressor-unbound PPARg is higher than that for PPARg-NCoR complex and that this is probably due to the conformational Table 1. change of PPARg induced by the interaction of NCoR peptide with PPARg.
Affinity of Ligand-PPARg g Complex for Coactivator
To investigate whether FK614 induces differential affinity of PPARg for coactivator compared with other TZDs, estimated K d values for the peptide from human CBP were determined using HTRF assays. Figure 5A shows saturation binding curves for CBP peptide in the presence of 10 mM FK614, 10 mM rosiglitazone, or 100 mM pioglitazone. At 20 mM CBP peptide, binding of CBP peptide to PPARg was almost saturated in the presence of rosiglitazone. Since, it was assumed that HTRF signal indicates the amount of CBP peptide that binds to all PPARg, in the presence of 20 mM CBP peptide and 10 mM rosiglitazone. Furthermore, it has been shown by X-ray crystal structure analysis that coactivators bind to PPARg at a ratio of 1 mol coactivator:1 mol PPARg in the presence of ligands. 26, 27) Therefore, it was also assumed that CBP binding at saturation approaches a ratio of 1 mol coactivator:1 mol PPARg. Amounts of free and bound CBP peptide under the all conditions were then estimated. Linear regression analysis of bound/free versus bound Scatchard transformation data yielded estimated K d values of 1.9, 0.64, and 0.72 mM in the presence of FK614, rosiglitazone, and pioglitazone, respectively (Fig. 5B) . The estimated K d value of FK614-PPARg complex to CBP peptide was 3.0-and 2.7-fold larger than that of rosiglitazone-and pioglitazonePPARg complex, respectively. These results indicate that FK614-PPARg complex exhibits low affinity compared to other TZD-PPARg complexes in CBP peptide binding, presumably due to the different conformational changes of PPARg induced by FK614.
Negative Modulation of 9(S)-HODE-Induced Coactivator Recruitment to PPARg g by FK614 To address the possibility that FK614 negatively regulates biological responses evoked by endogenous ligands, the effect of FK614 on coactivator recruitment promoted by 9(S)-HODE was examined by GST pull-down assay. As shown in Fig. 6, FK614 caused a concentration dependent decrease in magnitude of CBP binding to PPARg induced by 9(S)-HODE, inhibiting to the level obtained by stimulation with FK614 alone. This inhibitory effect was observed even at 10 nM FK614, which is in good agreement with results obtained in ligand binding and FK614-promoted coactivator recruitment experiments. On the other hand, 10 mM rosiglitazone did not inhibit CBP peptide recruitment to PPARg induced by 9(S)-HODE (data not shown). These results demonstrate that the biological effect of 9(S)-HODE, an efficacious endogenous agonist for PPARg, can be modulated negatively by FK614. DISCUSSION FK614, a structurally novel class of PPARg agonist incorporating a sulfonylcarbamoyl moiety as a key pharmacophore, improves hyperglycemia in diabetic db/db mice. 23) FK614 has been shown to promote PPARg-mediated transcription in cell-based reporter gene assay, 23) suggesting that FK614 exerts its pharmacological effects through PPARg activation, like the previously reported rosiglitazone and pioglitazone.
2) In this study, FK614 behaved as a novel class of PPARg ligand with unique properties in PPARg activation.
First, we focused on the binding of FK614 to PPARg and the effect of FK614 on conformational change of PPARg. Competitive binding analysis showed that FK614 competes In protease protection assays, FK614 altered protease sensitivity of PPARg and generated ligand-like protection patterns 24, 28) that can be observed in rosiglitazone-bound receptor. These results clearly indicate that FK614 can directly bind to PPARg and induce a conformational change in PPARg. In the binding assay, FK614 showed a distinctly steeper slope for the displacement curve. Furthermore, in limited protease sensitivity assay, FK614 induced a stronger protection of the 32 kDa fragment, also the 25 kDa fragment, that was not present in rosiglitazone-treated samples, was faintly detected in FK614-bound receptor. These observed differences strongly suggest that the conformational changes induced by FK614 in PPARg were slightly different from those by TZD compounds, presumably because FK614 interacts with PPARg in a different manner. These results show that FK614 can alter the conformation of PPARg upon direct binding and suggest that it could lead to differential biological responses compared to other TZDs, while those compounds act on PPARg as a primary site of action. The coefficient of Hill plot for FK614 was higher than that for other TZD compounds. This observation suggests a positive cooperative interaction of FK614 with PPARg. Although further investigation is required to characterize the mechanism of interaction of FK614 with PPARg, it may be possible that dimerization of the receptor 26) exhibits a cooperative interaction, like interaction of estradiol with the estrogen receptor. 29) Binding of FK614 to one component of a possible PPARg homodimer may lead to an allosteric conformational change enhancing the affinity of the other unoccupied component for FK614. Alternatively, similar to 4-hydroxytamoxifen binding that inhibits estradiol binding to estrogen receptor, 30) PPARg may have different binding sites for FK614 and rosiglitazone, and binding of FK614 to PPARg may reduce the affinity of rosiglitazone binding to PPARg.
Second, we focused on the interaction between transcriptional cofactors and PPARg, and examined the effects of FK614, rosiglitazone, and pioglitazone on the recruitment of coactivator to PPARg in vitro. FK614, as well as other compounds, promotes corepressor release and coactivator recruitment to PPARg, behaving as a PPARg agonist. In this study, the maximal effect of FK614 in coactivator recruitment was much lower than other compounds, as the FK614-PPARg complex exhibits lower affinity for the CBP peptide than other ligand-PPARg complexes. In previous studies, the maximal effect of FK614 on PPARg mediated transcription in cell-based reporter gene assay was lower than other compounds, such as rosiglitazone and pioglitazone. 23) This strongly suggests that the partial-agonistic feature of FK614 observed in reporter gene assay is due to the lower magnitude of recruitment of coactivators to FK614-PPARg complexes. The effect of rosiglitazone on CBP recruitment was initiated at a concentration of 10 nM, increasing gradually to reach a plateau at 1 mM. FK614-induced recruitment was also initiated at a concentration of the same order of magnitude as rosiglitazone, in the plateau. These observations are consistent with the rank order of potencies in the binding study. Interestingly, estimated K d value of FK614-PPARg complex was larger than that of rosiglitazone-and pioglitazonePPARg complex in CBP peptide binding. These results suggest that FK614 is a potent ligand for receptor occupancy, but produces receptor conformations with reduced affinity for coactivators. Thus, FK614 behaves as a high affinity ligand for PPARg with low intrinsic activity. Therefore, at this point FK614 is clearly distinguishable from other TZD compounds.
Finally, we focused on the possibility that FK614 negatively modulates PPARg-activity induced by endogenous ligand, and examined the effect of FK614 on 9(S)-HODE-induced coactivator recruitment using GST pull-down assay. 9(S)-HODE promoted coactivator recruitment to PPARg and behaved as a PPARg agonist. Magnitude of coactivator recruitment achieved by 9(S)-HODE was greater than that of the maximal response of FK614, indicating that 9(S)-HODE is more efficacious than FK614. FK614 caused a concentration-dependent decrease in the magnitude of CBP binding to PPARg induced by 9(S)-HODE and inhibited the level obtained when stimulated by FK614 alone. This inhibitory effect was observed even at low concentrations of FK614, which is in good agreement with results obtained in ligand binding and FK614-promoted coactivator recruitment experiments. As FK614 is a potent ligand in receptor occupancy, FK614 competes effectively with 100 mM 9(S)-HODE even at low concentrations. The results described above indicate that, unlike the full-agonists, FK614 negatively modulates PPARg-activity induced by 9(S)-HODE. High concentrations of 9(S)-HODE were required to obtain activation of coactivator recruitment. In tissues containing high amounts of 9(S)-HODE, such as macrophage, biological effects mediated by such endogenous ligands may be negatively regulated by FK614. Thus, FK614 could behave as a tissue-and stagespecific PPARg modulator that activates or represses PPARgmediated pathways, depending on the cell context of target tissues. 9(S)-HODE is an oxidative metabolite of linoleic acid, a major oxidized lipid component of oxidized LDL, 4, 5) and is present at high levels in atherosclerotic lesions. 6) 9(S)-HODE-mediated PPARg activation is involved in many cellular events, including fatty acid influx, 4) foam cell formation, 4) VEGF expression, 7) and cholesterol efflux, 8, 9) thus is believed to exert both pro-and anti-atherogenic effects on macrophages. 31) In atherosclerotic lesion development, high concentration of 9(S)-HODE may exert its atherogenic effect on macrophages by inducing the expression of CD36, a scavenger receptor, which mediates oxidized LDL uptake into macrophages and induces foam cell formation. 4) Namely, scavenger receptor substrate, such as oxidized LDL initiates and promotes its own uptake by increasing the level of receptor expression. It is expected that selective PPARg modulators like FK614 may negatively modulate CD36 expression induced by endogenous ligands and exert an anti-atherogenic effect. As PPARg agonists are used in type 2 diabetic patients at high risk of developing complications of atherosclerosis, these observations have important clinical implications. Therapeutic benefits of generations of PPARg ligands in patients with type 2 diabetes could presumably be greatly enhanced by selecting compounds that retain insulin-sensitizing activities and are optimized for their anti-atherogenic activities, 31) such as compounds like FK614. FK614 has selective PPARg partial agonist activity as do previously reported partial agonists, such as troglitazone, 13) MCC-555, 32) GW0072, 12) PAT5A, 14) and nTZDpa. 15) Many of these compounds have potent hypoglycemic and hypotriglyceridemic activities in animal models of type 2 diabetes. 15, [33] [34] [35] However, previous studies have not reported whether these compounds negatively modulate PPARg-activity promoted by endogenous ligands, such as 9(S)-HODE. Therefore, FK614 may differ from other selective PPARg partial agonists, and may have better efficacy as therapy for arteriosclerosis as well as type 2 diabetes.
In relation to diabetes mellitus, it has been reported that heterozygous PPARg deficient mice are protected from highfat diet-induced insulin resistance. 36, 37) Consistent with this observation, Pro12Ala polymorphism in human PPARg2, that moderately reduces transcriptional activity of PPARg, has been shown to confer resistance to type 2 diabetes. 38) Recently, appropriate functional antagonism of PPARg/RXR by administration of PPARg-antagonist was demonstrated to be a beneficial approach against insulin resistance.
39) Therefore maintenance of PPARg activation in appropriate levels by a PPARg modulator like FK614 may lead to therapeutic benefits for the control of insulin resistance.
In conclusion, FK614 can bind to PPARg as an agonist that shows differential properties in coactivator recruitment compared to other TZD ligands, due to distinct conformational changes of PPARg. These distinct properties of FK614 may lead to different biological responses compared to other insulin-sensitizing compounds.
